PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH SECOND LINE ERLOTINIB/GEFITINIB WHO FAILED TO PREVIOUS CHEMOTHERAPY

Madolangan Jamaluddin; Hudoyo Ahmad; Andarini Sita

首页> 外文期刊>Respirology : >PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH SECOND LINE ERLOTINIB/GEFITINIB WHO FAILED TO PREVIOUS CHEMOTHERAPY

【24h】

PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH SECOND LINE ERLOTINIB/GEFITINIB WHO FAILED TO PREVIOUS CHEMOTHERAPY

机译：曾接受过第二次化疗的厄洛替尼/吉非替尼二线治疗的晚期非小细胞肺癌（NSCLC）患者的无进展生存期（PFS）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Respirology :》 |2015年第3期|共1页
作者
Madolangan Jamaluddin; Hudoyo Ahmad; Andarini Sita;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类呼吸系及胸部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH SECOND LINE ERLOTINIB/GEFITINIB WHO FAILED TO PREVIOUS CHEMOTHERAPY [J] . Madolangan Jamaluddin, Hudoyo Ahmad, Andarini Sita Respirology : . 2015,第Suppla3期

机译：曾接受过第二次化疗的厄洛替尼/吉非替尼二线治疗的晚期非小细胞肺癌（NSCLC）患者的无进展生存期（PFS）
2. Continuation of gefitinib plus chemotherapy prolongs progression- free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations [J] . Ting Ding, Fei Zhou, Xiaoxia Chen, Journal of Thoracic Disease . 2017,第9期

机译：Gefitinib Plus化疗的延续延长了在未经T790M突变的情况下获得对吉替尼的抗性的先进非小细胞肺癌患者的无进展生存
3. Design of clinical studies: Adaptive randomization and progression-free survival (PFS) as an endpoint in clinical studies of advanced non-small cell lung cancer (NSCLC) [J] . SchrimpfD., ManegoldC., PilzL.R. International journal of clinical pharmacology and therapeutics . 2013,第1期

机译：临床研究设计：适应性随机分组和无进展生存期（PFS）作为晚期非小细胞肺癌（NSCLC）临床研究的终点
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Assessing the effectiveness of palliative chemotherapy for non-small cell lung cancer: A phase IV study of patients treated at Ontario's cancer centres [D] . Harrison, Lyndsay Dawn. 2012

机译：评估姑息化疗对非小细胞肺癌的有效性：在安大略省癌症中心接受治疗的患者的IV期研究
6. Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations [O] . Ting Ding, Fei Zhou, Xiaoxia Chen, 2017

机译：吉非替尼加化学疗法的继续治疗可延长晚期非小细胞肺癌患者的无进展生存期这些患者对吉非替尼具有无T790M突变的获得性耐药
7. Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations [O] . Ting Ding, Fei Zhou, Xiaoxia Chen, 2017

机译：Gefitinib Plus化疗的延续延长了高级非小细胞肺癌患者的无进展生存率，他们因没有T790M突变而获得吉维替尼的抗性

PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH SECOND LINE ERLOTINIB/GEFITINIB WHO FAILED TO PREVIOUS CHEMOTHERAPY

著录项

相似文献

相关主题

期刊订阅